Sulzer Medica buys into arthroscopy:
This article was originally published in Clinica
Executive Summary
Sulzer Medica has boosted its orthopaedics division through the acquisition of German company Friatec's arthroscopy business. Felix Scherrer, president of Sulzer Orthopedics, said the acquisition marked the first significant step in the expansion of the arthroscopic business. Swiss company Sulzer Medica also manufactures products for the cardiovascular markets. Friatec's arthroscopic business generates SwFr4 million ($2.6 million) in annual sales.
You may also be interested in...
Executives On The Move: Changes At The Top At Enzolytics, Dyne Therapeutics And Seres Therapeutics
Recent moves in the industry include new chief financial officers at LENZ Therapeutics and Botanix Pharmaceuticals, plus new chief medical officers at Vigil Neuroscience and Voyager Therapeutics.
Israel's Gamida Cell Survives By Selling To Lender
Having finally secured US approval for Omisirge, Gamida was hoping to bag a strategic partner for the cell therapy. A year on, no suitable partner has been identified and the firm is delisting from the NASDAQ and going private.
EU Regulatory Assessors Get AI Boost In Reaching Scientific Decisions
The European Medicines Agency is training scientific staff working for the European medicines regulatory network in how to use a new AI-powered search engine that allows them to easily retrieve information on regulatory precedents.